FDA Commissioner Marty Makary stated publicly: "We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms." The regulatory environment around GLP-1-adjacent products is tightening
Administered once weekly, GLP-1 therapy injections have been shown to result in weight loss exceeding 50 pounds in as little as six months an attractive option for individuals looking to achieve substantial weight reduction efficiently
Some patients may experience mild appetite suppression at very low doses of GLP-1 medications, but this effect is usually too small and weaker than the standard therapeutic doses
Medium needles (6mm) suit most body types and represent the most commonly recommended length
Retatrutide works by mimicking the actions of three important hormones: GLP-1, GIP and GCG
The following dosing information is compiled from individual compound clinical trial data, peptide research community reports, and the pharmacological profiles of each compound